Get the Stockscreener App
25.56
7.53%
1.79
After Hours:
26.25
0.69
+2.70%
Septerna Inc stock is traded at $25.56, with a volume of 345.29K.
It is up +7.53% in the last 24 hours and up +19.94% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$23.77
Open:
$23.64
24h Volume:
345.29K
Relative Volume:
1.12
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.86%
1M Performance:
+19.94%
6M Performance:
+182.12%
1Y Performance:
+17.30%
1-Day Range:
$23.55
$26.25
1-Week Range:
$21.31
$26.25
52-Week Range:
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
25.56 | 1.06B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
Cantor Fitzgerald maintains Overweight rating on Septerna stock at $25 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains Overweight rating on Septerna stock at $25 - Investing.com India
Is Septerna Inc. stock affected by interest rate hikesMarket Performance Recap & Real-Time Volume Surge Alerts - newser.com
What is the fair value of Septerna Inc. stock nowGDP Growth & Reliable Momentum Entry Alerts - newser.com
Statistical indicators supporting Septerna Inc.’s strengthJuly 2025 Chart Watch & Risk Controlled Daily Trade Plans - newser.com
How to recover losses in Septerna Inc. stockMarket Growth Review & Accurate Technical Buy Alerts - newser.com
Will Septerna Inc. stock rally after Fed decisionsTrade Entry Report & Weekly Chart Analysis and Guides - newser.com
Why analysts upgrade Septerna Inc. stockMarket Sentiment Review & Safe Capital Growth Stock Tips - newser.com
Trend analysis for Septerna Inc. this weekShort Setup & Real-Time Volume Triggers - newser.com
Pattern recognition hints at Septerna Inc. upsideJuly 2025 Drop Watch & Low Drawdown Trading Techniques - newser.com
Why Septerna (SEPN) Is Up 28.5% After Posting a Surprise Profit and Analyst Upgrades - Yahoo Finance
Is Septerna Inc. stock ready for a breakout2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Septerna (SEPN) Price Target Increased by 20.29% to 28.22 - Nasdaq
How to monitor Septerna Inc. with trend dashboards2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
Is Septerna Inc. stock a defensive play in 20252025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Septerna (SEPN) Is Up 25.7% After Turning Profitable on Strong Q3 Sales and Analyst Optimism Has The Bull Case Changed? - simplywall.st
A Look at Septerna (SEPN) Valuation Following Strong Q3 Sales and Swing to Profitability - Yahoo Finance
Is Septerna Inc. stock a safe haven assetMarket Risk Report & Real-Time Volume Trigger Notifications - newser.com
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Applied Materials (AMAT) and Nvidia (NVDA) - The Globe and Mail
Combining price and volume data for Septerna Inc.Trade Analysis Summary & Safe Capital Growth Tips - newser.com
Wells Fargo Upgrades Septerna (SEPN) - Nasdaq
Septerna Shares Rise After Wells Fargo Upgrade - MarketScreener
Septerna stock surges after Wells Fargo upgrade By Investing.com - Investing.com UK
Septerna stock surges after Wells Fargo upgrade - Investing.com
Septerna (SEPN) Receives Analyst Upgrade and Increased Price Tar - GuruFocus
Is Septerna Inc. stock a dividend growth opportunityJuly 2025 Breakouts & Growth Focused Stock Reports - Fundação Cultural do Pará
Wells upgrades Septerna to Overweight on 2026 share catalysts - TipRanks
Using data filters to optimize entry into Septerna Inc.July 2025 Selloffs & Technical Confirmation Trade Alerts - newser.com
Long Daniel D., Septerna SVP, drug discovery, sells $63k in shares By Investing.com - Investing.com Nigeria
Long Daniel D., Septerna SVP, drug discovery, sells $63k in shares - Investing.com Canada
Septerna SVP Daniel D. Long Sells 3,501 Shares - TradingView
[Form 4] Septerna, Inc. Insider Trading Activity - Stock Titan
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):